The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells

Summary Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clini...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunology 2013-02, Vol.138 (2), p.105-115
Hauptverfasser: Lindau, Dennis, Gielen, Paul, Kroesen, Michiel, Wesseling, Pieter, Adema, Gosse J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 115
container_issue 2
container_start_page 105
container_title Immunology
container_volume 138
creator Lindau, Dennis
Gielen, Paul
Kroesen, Michiel
Wesseling, Pieter
Adema, Gosse J.
description Summary Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.
doi_str_mv 10.1111/imm.12036
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3575763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3311575031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</originalsourceid><addsrcrecordid>eNqNkctqFTEYgINY7LG68AUk4Eah0-YySWa6EKRYW2hxc1yHTJJp02Ymx2TSw9n5CD6jT2KO01NUEMwml__Lx38B4BVGR7isYzcMR5ggyp-ABaacVYRx8RQsEMJtRRrE9sHzlG7LlSLGnoF9QgnmHJEFWC9vLCz_8xhSXq2iTcndWzjlIeQIRzutQ7w7gcPG-uDMj2_fjY0FMHBHhwi19T4dwmivs1dTiBu4nN-gGg0c1ZSj8vDOeW_jLvQC7PXKJ_vyYT8AX84-Lk_Pq8vPny5OP1xWuhacV3Vnuqa3RDWaGNO0umOiU1QroXhreN2hti_nngoqrFBEa14IhupO9A0Thh6A97N3lbvBGm3HqSQjV9ENKm5kUE7-GRndjbwO95IWjeC0CN4-CGL4mm2a5ODStgQ12pCTxKRhqG0ZRv-BCsoahtu6oG_-Qm9Lv8fSCYkZ4W0jENkK382UjiGlaPvHvDGS28nLMjn5a_KFff17oY_kbtQFOJ6BtfN282-TvLi6mpU_AVUjvDw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1526987020</pqid></control><display><type>article</type><title>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Lindau, Dennis ; Gielen, Paul ; Kroesen, Michiel ; Wesseling, Pieter ; Adema, Gosse J.</creator><creatorcontrib>Lindau, Dennis ; Gielen, Paul ; Kroesen, Michiel ; Wesseling, Pieter ; Adema, Gosse J.</creatorcontrib><description>Summary Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.</description><identifier>ISSN: 0019-2805</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1111/imm.12036</identifier><identifier>PMID: 23216602</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Animals ; Antigen-Presenting Cells - immunology ; Antigen-Presenting Cells - pathology ; Cell Communication - immunology ; Humans ; Immune Tolerance ; immunocombination therapy ; Immunotherapy - methods ; Medical research ; Myeloid Cells - immunology ; Myeloid Cells - pathology ; myeloid‐derived suppressor cell ; natural killer T cell ; Natural Killer T-Cells - immunology ; Natural Killer T-Cells - pathology ; Neoplasms - immunology ; Neoplasms - pathology ; Neoplasms - therapy ; regulatory T cell ; Review ; T cell receptors ; T-Lymphocytes, Regulatory - immunology ; T-Lymphocytes, Regulatory - pathology ; tumour microenvironment</subject><ispartof>Immunology, 2013-02, Vol.138 (2), p.105-115</ispartof><rights>2012 Nijmegen Centre for Molecular Life Sciences © 2012 Blackwell Publishing Ltd</rights><rights>2012 Nijmegen Centre for Molecular Life Sciences Immunology © 2012 Blackwell Publishing Ltd.</rights><rights>Copyright © 2013 Blackwell Publishing Ltd</rights><rights>Copyright © 2013 Blackwell Publishing Ltd 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</citedby><cites>FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575763/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575763/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1416,1432,27922,27923,45572,45573,46407,46831,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23216602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lindau, Dennis</creatorcontrib><creatorcontrib>Gielen, Paul</creatorcontrib><creatorcontrib>Kroesen, Michiel</creatorcontrib><creatorcontrib>Wesseling, Pieter</creatorcontrib><creatorcontrib>Adema, Gosse J.</creatorcontrib><title>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</title><title>Immunology</title><addtitle>Immunology</addtitle><description>Summary Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.</description><subject>Animals</subject><subject>Antigen-Presenting Cells - immunology</subject><subject>Antigen-Presenting Cells - pathology</subject><subject>Cell Communication - immunology</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>immunocombination therapy</subject><subject>Immunotherapy - methods</subject><subject>Medical research</subject><subject>Myeloid Cells - immunology</subject><subject>Myeloid Cells - pathology</subject><subject>myeloid‐derived suppressor cell</subject><subject>natural killer T cell</subject><subject>Natural Killer T-Cells - immunology</subject><subject>Natural Killer T-Cells - pathology</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>regulatory T cell</subject><subject>Review</subject><subject>T cell receptors</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>T-Lymphocytes, Regulatory - pathology</subject><subject>tumour microenvironment</subject><issn>0019-2805</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctqFTEYgINY7LG68AUk4Eah0-YySWa6EKRYW2hxc1yHTJJp02Ymx2TSw9n5CD6jT2KO01NUEMwml__Lx38B4BVGR7isYzcMR5ggyp-ABaacVYRx8RQsEMJtRRrE9sHzlG7LlSLGnoF9QgnmHJEFWC9vLCz_8xhSXq2iTcndWzjlIeQIRzutQ7w7gcPG-uDMj2_fjY0FMHBHhwi19T4dwmivs1dTiBu4nN-gGg0c1ZSj8vDOeW_jLvQC7PXKJ_vyYT8AX84-Lk_Pq8vPny5OP1xWuhacV3Vnuqa3RDWaGNO0umOiU1QroXhreN2hti_nngoqrFBEa14IhupO9A0Thh6A97N3lbvBGm3HqSQjV9ENKm5kUE7-GRndjbwO95IWjeC0CN4-CGL4mm2a5ODStgQ12pCTxKRhqG0ZRv-BCsoahtu6oG_-Qm9Lv8fSCYkZ4W0jENkK382UjiGlaPvHvDGS28nLMjn5a_KFff17oY_kbtQFOJ6BtfN282-TvLi6mpU_AVUjvDw</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Lindau, Dennis</creator><creator>Gielen, Paul</creator><creator>Kroesen, Michiel</creator><creator>Wesseling, Pieter</creator><creator>Adema, Gosse J.</creator><general>Wiley Subscription Services, Inc</general><general>Blackwell Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QR</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201302</creationdate><title>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</title><author>Lindau, Dennis ; Gielen, Paul ; Kroesen, Michiel ; Wesseling, Pieter ; Adema, Gosse J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antigen-Presenting Cells - immunology</topic><topic>Antigen-Presenting Cells - pathology</topic><topic>Cell Communication - immunology</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>immunocombination therapy</topic><topic>Immunotherapy - methods</topic><topic>Medical research</topic><topic>Myeloid Cells - immunology</topic><topic>Myeloid Cells - pathology</topic><topic>myeloid‐derived suppressor cell</topic><topic>natural killer T cell</topic><topic>Natural Killer T-Cells - immunology</topic><topic>Natural Killer T-Cells - pathology</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>regulatory T cell</topic><topic>Review</topic><topic>T cell receptors</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>T-Lymphocytes, Regulatory - pathology</topic><topic>tumour microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindau, Dennis</creatorcontrib><creatorcontrib>Gielen, Paul</creatorcontrib><creatorcontrib>Kroesen, Michiel</creatorcontrib><creatorcontrib>Wesseling, Pieter</creatorcontrib><creatorcontrib>Adema, Gosse J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindau, Dennis</au><au>Gielen, Paul</au><au>Kroesen, Michiel</au><au>Wesseling, Pieter</au><au>Adema, Gosse J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</atitle><jtitle>Immunology</jtitle><addtitle>Immunology</addtitle><date>2013-02</date><risdate>2013</risdate><volume>138</volume><issue>2</issue><spage>105</spage><epage>115</epage><pages>105-115</pages><issn>0019-2805</issn><eissn>1365-2567</eissn><abstract>Summary Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>23216602</pmid><doi>10.1111/imm.12036</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0019-2805
ispartof Immunology, 2013-02, Vol.138 (2), p.105-115
issn 0019-2805
1365-2567
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3575763
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; IngentaConnect Free/Open Access Journals; Wiley Online Library All Journals; PubMed Central
subjects Animals
Antigen-Presenting Cells - immunology
Antigen-Presenting Cells - pathology
Cell Communication - immunology
Humans
Immune Tolerance
immunocombination therapy
Immunotherapy - methods
Medical research
Myeloid Cells - immunology
Myeloid Cells - pathology
myeloid‐derived suppressor cell
natural killer T cell
Natural Killer T-Cells - immunology
Natural Killer T-Cells - pathology
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
regulatory T cell
Review
T cell receptors
T-Lymphocytes, Regulatory - immunology
T-Lymphocytes, Regulatory - pathology
tumour microenvironment
title The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T02%3A57%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20immunosuppressive%20tumour%20network:%20myeloid%E2%80%90derived%20suppressor%20cells,%20regulatory%20T%20cells%20and%20natural%20killer%20T%20cells&rft.jtitle=Immunology&rft.au=Lindau,%20Dennis&rft.date=2013-02&rft.volume=138&rft.issue=2&rft.spage=105&rft.epage=115&rft.pages=105-115&rft.issn=0019-2805&rft.eissn=1365-2567&rft_id=info:doi/10.1111/imm.12036&rft_dat=%3Cproquest_pubme%3E3311575031%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1526987020&rft_id=info:pmid/23216602&rfr_iscdi=true